As of Q3'25, Pfizer's ROS (Return on Sales) stands at 19.97%, reflecting a stable profitability level in the most recent quarter. The latest available data point shows a slight decrease from the previous quarter's 20.82%, but remains within a consistent range. Over the period from Q1'23 to Q3'25, the ROS has exhibited significant volatility, with sharp declines into negative territory in Q3'23 (-25.29%) and Q4'23 (-29.22%), followed by a strong recovery to positive values in 2024 and 2025. After this period of instability, the ROS has stabilized above 19% for the last three reported quarters, indicating improved operational efficiency and a return to more consistent profitability.